Metabolically engineered Escherichia coli for efficient production of glycosylated natural products.
Significant achievements in polyketide gene expression have made Escherichia coli one of the most promising hosts for the heterologous production of pharmacologically important polyketides. However, attempts to produce glycosylated polyketides, by the expression of heterologous sugar pathways, have been hampered until now by the low levels of glycosylated compounds produced by the recombinant hosts. By carrying out metabolic engineering of three endogenous pathways that lead to the synthesis of TDP sugars in E. coli, we have greatly improved the intracellular levels of the common deoxysugar intermediate TDP-4-keto-6-deoxyglucose resulting in increased production of the heterologous sugars TDP-L-mycarose and TDP-D-desosamine, both components of medically important polyketides. Bioconversion experiments carried out by feeding 6-deoxyerythronolide B (6-dEB) or 3-α-mycarosylerythronolide B (MEB) demonstrated that the genetically modified E. coli B strain was able to produce 60- and 25-fold more erythromycin D (EryD) than the original strain K207-3, respectively. Moreover, the additional knockout of the multidrug efflux pump AcrAB further improved the ability of the engineered strain to produce these glycosylated compounds. These results open the possibility of using E. coli as a generic host for the industrial scale production of glycosylated polyketides, and to combine the polyketide and deoxysugar combinatorial approaches with suitable glycosyltransferases to yield massive libraries of novel compounds with variations in both the aglycone and the tailoring sugars.
Microbiology Division, IBR (Instituto de Biología Molecular y Celular de Rosario), Consejo Nacional de Investigaciones Científicas y Técnicas, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina.
Salvador
S
Peirú
Eduardo
E
Rodríguez
Hugo G
HG
Menzella
John R
JR
Carney
Hugo
H
Gramajo
D001688:Biological Products / Q000235:genetics / Q000378:metabolism*; D053898:Biosynthetic Pathways; D004926:Escherichia coli / Q000235:genetics* / Q000378:metabolism*; D029968:Escherichia coli Proteins / Q000235:genetics / Q000378:metabolism; D005818:Genetic Engineering; D006031:Glycosylation; D018942:Macrolides / Q000378:metabolism*
D001688:Biological Products; D029968:Escherichia coli Proteins; D018942:Macrolides
BMC Microbiol. 2002 Jul 09;2:18
12106505
J Bacteriol. 2006 Jul;188(14):5124-35
16816184
Antimicrob Agents Chemother. 1985 Nov;28(5):630-3
4091529
Trends Biotechnol. 2001 Nov;19(11):449-56
11602309
PLoS Biol. 2007 Feb;5(2):e45
17298179
Microbiology (Reading). 2006 Mar;152(Pt 3):667-673
16514147
J Bacteriol. 2006 Aug;188(15):5606-17
16855251
Science. 2001 Mar 2;291(5509):1790-2
11230695
Nat Biotechnol. 2005 Sep;23(9):1171-6
16116420
Antimicrob Agents Chemother. 2001 Apr;45(4):1126-36
11257026
Bioorg Med Chem. 2004 Apr 1;12(7):1577-84
15112655
Appl Environ Microbiol. 2005 May;71(5):2539-47
15870344
J Biol Chem. 1992 Jan 15;267(2):746-53
1730666
Curr Opin Microbiol. 2007 Jun;10(3):238-45
17553731
J Bacteriol. 2001 Oct;183(20):5803-12
11566977
Microbiology (Reading). 1999 Sep;145 ( Pt 9):2485-2495
10517601
Biochemistry. 2007 Jul 10;46(27):8100-9
17571859
Chem Biol. 2004 Jul;11(7):915-25
15271350
J Ind Microbiol Biotechnol. 2003 Aug;30(8):500-9
12898389
J Bacteriol. 2006 Nov;188(21):7542-50
16936038
Chem Rev. 1997 Nov 10;97(7):2465-2498
11851466
J Bacteriol. 2007 Dec;189(23):8626-35
17905981
Chem Biol. 2004 Dec;11(12):1709-18
15610855
J Biotechnol. 2004 May 13;110(1):95-103
15099909
Chem Biol. 2007 Feb;14(2):143-51
17317568
J Bacteriol. 1999 Oct;181(20):6564-8
10515954
Biochim Biophys Acta. 1960 Feb 26;38:384-6
14428528
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5
10829079
Trends Microbiol. 2007 May;15(5):219-32
17412593
Biochemistry. 2006 Jan 31;45(4):1321-30
16430229